

# Michael L-H Huang

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7512909/publications.pdf>

Version: 2024-02-01

45  
papers

2,525  
citations

236833

25  
h-index

265120

42  
g-index

47  
all docs

47  
docs citations

47  
times ranked

4253  
citing authors

#	ARTICLE	IF	CITATIONS
1	Mitochondrial iron trafficking and the integration of iron metabolism between the mitochondrion and cytosol. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 10775-10782.	3.3	413
2	Cellular iron uptake, trafficking and metabolism: Key molecules and mechanisms and their roles in disease. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2015, 1853, 1130-1144.	1.9	275
3	Elucidation of the mechanism of mitochondrial iron loading in Friedreich's ataxia by analysis of a mouse mutant. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 16381-16386.	3.3	197
4	Roads to melanoma: Key pathways and emerging players in melanoma progression and oncogenic signaling. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2016, 1863, 770-784.	1.9	148
5	Hepcidin, the hormone of iron metabolism, is bound specifically to Î±2-macroglobulin in blood. <i>Blood</i> , 2009, 113, 6225-6236.	0.6	111
6	Redox cycling metals: Pedaling their roles in metabolism and their use in the development of novel therapeutics. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2016, 1863, 727-748.	1.9	111
7	Copper and conquer: copper complexes of di-2-pyridylketone thiosemicarbazones as novel anti-cancer therapeutics. <i>Metallomics</i> , 2016, 8, 874-886.	1.0	105
8	The Role of the Antioxidant Response in Mitochondrial Dysfunction in Degenerative Diseases: Cross-Talk between Antioxidant Defense, Autophagy, and Apoptosis. <i>Oxidative Medicine and Cellular Longevity</i> , 2019, 2019, 1-26.	1.9	92
9	Identification of nonferritin mitochondrial iron deposits in a mouse model of Friedreich ataxia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 20590-20595.	3.3	85
10	Mitochondrial Mayhem: The Mitochondrion as a Modulator of Iron Metabolism and Its Role in Disease. <i>Antioxidants and Redox Signaling</i> , 2011, 15, 3003-3019.	2.5	84
11	The role of NDRG1 in the pathology and potential treatment of human cancers. <i>Journal of Clinical Pathology</i> , 2013, 66, 911-917.	1.0	72
12	The proto-oncogene c-Src and its downstream signaling pathways are inhibited by the metastasis suppressor, NDRG1. <i>Oncotarget</i> , 2015, 6, 8851-8874.	0.8	64
13	Molecular and Functional Alterations in a Mouse Cardiac Model of Friedreich Ataxia. <i>American Journal of Pathology</i> , 2013, 183, 745-757.	1.9	62
14	The ins and outs of mitochondrial iron-loading: the metabolic defect in Friedreich's ataxia. <i>Journal of Molecular Medicine</i> , 2010, 88, 323-329.	1.7	55
15	Pharmacological targeting of mitochondria in cancer stem cells: An ancient organelle at the crossroad of novel anti-cancer therapies. <i>Pharmacological Research</i> , 2019, 139, 298-313.	3.1	55
16	Molecular Alterations in a Mouse Cardiac Model of Friedreich Ataxia. <i>American Journal of Pathology</i> , 2017, 187, 2858-2875.	1.9	51
17	Fixing frataxin: "ironing out" the metabolic defect in Friedreich's ataxia. <i>British Journal of Pharmacology</i> , 2014, 171, 2174-2190.	2.7	46
18	Targeting the Metastasis Suppressor, N-Myc Downstream Regulated Gene-1, with Novel Di-2-Pyridylketone Thiosemicarbazones: Suppression of Tumor Cell Migration and Cell-Collagen Adhesion by Inhibiting Focal Adhesion Kinase/Paxillin Signaling. <i>Molecular Pharmacology</i> , 2016, 89, 521-540.	1.0	45

#	ARTICLE	IF	CITATIONS
19	Frataxin and the molecular mechanism of mitochondrial iron-loading in Friedreich's ataxia. <i>Clinical Science</i> , 2016, 130, 853-870.	1.8	45
20	The metastasis suppressor, NDRG1, attenuates oncogenic TGF- $\beta^2$ and NF- $\kappa$ B signaling to enhance membrane E-cadherin expression in pancreatic cancer cells. <i>Carcinogenesis</i> , 2019, 40, 805-818.	1.3	45
21	The molecular effect of metastasis suppressors on Src signaling and tumorigenesis: new therapeutic targets. <i>Oncotarget</i> , 2015, 6, 35522-35541.	0.8	43
22	Mitochondrial dysfunction in the neuro-degenerative and cardio-degenerative disease, Friedreich's ataxia. <i>Neurochemistry International</i> , 2018, 117, 35-48.	1.9	38
23	Tumor stressors induce two mechanisms of intracellular P-glycoprotein-mediated resistance that are overcome by lysosomal-targeted thiosemicarbazones. <i>Journal of Biological Chemistry</i> , 2018, 293, 3562-3587.	1.6	36
24	Potent Antimycobacterial Activity of the Pyridoxal Isonicotinoyl Hydrazone Analog 2-Pyridylcarboxaldehyde Isonicotinoyl Hydrazone: A Lipophilic Transport Vehicle for Isonicotinic Acid Hydrazide. <i>Molecular Pharmacology</i> , 2014, 85, 269-278.	1.0	33
25	Potentiating the cellular targeting and anti-tumor activity of Dp44mT via binding to human serum albumin: two saturable mechanisms of Dp44mT uptake by cells. <i>Oncotarget</i> , 2015, 6, 10374-10398.	0.8	28
26	Hepcidin Bound to $\pm$ 2-Macroglobulin Reduces Ferroportin-1 Expression and Enhances Its Activity at Reducing Serum Iron Levels. <i>Journal of Biological Chemistry</i> , 2013, 288, 25450-25465.	1.6	22
27	Novel Thiosemicarbazones Inhibit Lysine-Rich Carcinoembryonic Antigen-Related Cell Adhesion Molecule 1 (CEACAM1) Coisolated (LYRIC) and the LYRIC-Induced Epithelial-Mesenchymal Transition via Upregulation of N-Myc Downstream-Regulated Gene 1 (NDRG1). <i>Molecular Pharmacology</i> , 2017, 91, 499-517.	1.0	22
28	Biochemistry of cardiomyopathy in the mitochondrial disease Friedreich's ataxia. <i>Biochemical Journal</i> , 2013, 453, 321-336.	1.7	19
29	Exploiting Cancer Metal Metabolism using Anti-Cancer Metal-Binding Agents. <i>Current Medicinal Chemistry</i> , 2019, 26, 302-322.	1.2	19
30	Making a case for albumin as a highly promising drug-delivery system. <i>Future Medicinal Chemistry</i> , 2015, 7, 553-556.	1.1	17
31	Antioxidant defense mechanisms and its dysfunctional regulation in the mitochondrial disease, Friedreich's ataxia. <i>Free Radical Biology and Medicine</i> , 2020, 159, 177-188.	1.3	16
32	Treatment of dilated cardiomyopathy in a mouse model of Friedreich's ataxia using N-acetylcysteine and identification of alterations in microRNA expression that could be involved in its pathogenesis. <i>Pharmacological Research</i> , 2020, 159, 104994.	3.1	13
33	Mechanisms of impaired mitochondrial homeostasis and NAD <sup>+</sup> metabolism in a model of mitochondrial heart disease exhibiting redox active iron accumulation. <i>Redox Biology</i> , 2021, 46, 102038.	3.9	12
34	Acireductone dioxygenase 1 (ADI1) is regulated by cellular iron by a mechanism involving the iron chaperone, PCBP1, with PCBP2 acting as a potential co-chaperone. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2020, 1866, 165844.	1.8	8
35	Vesicular ATP-binding cassette transporters in human disease: relevant aspects of their organization for future drug development. <i>Future Drug Discovery</i> , 2020, 2, .	0.8	8
36	Novel multifunctional iron chelators of the aroyl nicotinoyl hydrazone class that markedly enhance cellular NAD <sup>+</sup> /NADH ratios. <i>British Journal of Pharmacology</i> , 2020, 177, 1967-1987.	2.7	7

#	ARTICLE	IF	CITATIONS
37	Hepcidin, show some self-control! How the hormone of iron metabolism regulates its own expression. <i>Biochemical Journal</i> , 2013, 452, e3-e5.	1.7	6
38	During mitosis ZEB1 “switches” from being a chromatin-bound epithelial gene repressor, to become a microtubule-associated protein. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2020, 1867, 118673.	1.9	6
39	The potential of the novel NAD+ supplementing agent, SNH6, as a therapeutic strategy for the treatment of Friedreich’s ataxia. <i>Pharmacological Research</i> , 2020, 155, 104680.	3.1	6
40	Letter to the Editor: “Analysis of the Interaction of Dp44mT with Human Serum Albumin and Calf Thymus DNA Using Molecular Docking and Spectroscopic Techniques” <i>International Journal of Molecular Sciences</i> , 2016, 17, 1916.	1.8	3
41	Incidence of Invasive Fungal Infections (IFI) in Pediatric Acute Lymphoblastic Leukemia (ALL) and the Impact of Antifungal Prophylaxis in an Endemic Area. <i>Blood</i> , 2021, 138, 1215-1215.	0.6	1
42	Targeting autophagy in antitumor agent design: furthering the “lysosomal love” strategy. <i>Future Medicinal Chemistry</i> , 2016, 8, 727-729.	1.1	0
43	Paradoxical disruption of Nrf2 signaling despite mitochondrial iron driven oxidative stress in Friedreich’s ataxia cardiomyopathy. <i>Free Radical Biology and Medicine</i> , 2018, 128, S131.	1.3	0
44	The dys-regulation of anti-oxidant defense via an impairment of Nrf2 response in the pathology of Friedreich’s ataxia. <i>Free Radical Biology and Medicine</i> , 2018, 120, S35.	1.3	0
45	Deciphering Mitochondrial Iron Metabolism Using a Knockout Mouse.. <i>Blood</i> , 2009, 114, 1995-1995.	0.6	0